Defining SOD1 ALS natural history to guide therapeutic clinical trial design-Reference-Cited by-同舟云学术

Defining SOD1 ALS natural history to guide therapeutic clinical trial design

Published:2016-06-03 Issue:2 Volume:88 Page:99-105
ISSN:0022-3050
Container-title:Journal of Neurology, Neurosurgery & Psychiatry
language:en
Short-container-title:J Neurol Neurosurg Psychiatry

Author:

Bali Taha,Self Wade,Liu Jingxia,Siddique Teepu,Wang Leo H,Bird Thomas D,Ratti Elena^ORCID,Atassi Nazem,Boylan Kevin B,Glass Jonathan D,Maragakis Nicholas J,Caress James B,McCluskey Leo F,Appel Stanley H,Wymer James P,Gibson Summer,Zinman Lorne,Mozaffar Tahseen,Callaghan Brian,McVey April L,Jockel-Balsarotti Jennifer,Allred Peggy,Fisher Elena R,Lopate Glenn,Pestronk Alan,Cudkowicz Merit E,Miller Timothy M

Publisher

BMJ

Subject

Psychiatry and Mental health,Clinical Neurology,Surgery

Reference30 articles.

1. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998;Sorenson;Neurology,2002

2. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology;Miller;Neurology,2009

3. Rate of familial amyotrophic lateral sclerosis: a systematic review and meta-analysis;Byrne;J Neurol Neurosurg Psychiatr,2011

4. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis;Rosen;Nature,1993

5. D90A heterozygosity in the SOD1 gene is associated with familial and apparently sporadic amyotrophic lateral sclerosis;Robberecht;Neurology,1996

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Body mass index is lower in asymptomatic C9orf72 expansion carriers but not in SOD1 pathogenic variant carriers compared to gene negatives;Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration;2024-08-27

2. Clinical characterization of common pathogenic variants of SOD1-ALS in Germany;Journal of Neurology;2024-08-14

3. Brain–body mechanisms contribute to sexual dimorphism in amyotrophic lateral sclerosis;Nature Reviews Neurology;2024-07-04

4. Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis;Expert Review of Neurotherapeutics;2024-05-17

5. Advancing the utilization of real‐world data and real‐world evidence in clinical pharmacology and translational research—Proceedings from the ASCPT 2023 preconference workshop;Clinical and Translational Science;2024-04